Alliance Pharma PLC Annual Report and Preliminary Results correction (7825T)

TIDMAPH

RNS Number : 7825T

Alliance Pharma PLC

29 March 2021

 
 For immediate release                                             29 March 2021 
 

ALLIANCE PHARMA PLC

("Alliance" or the "Group")

Annual Report and Accounts

and correction to FY2020 Preliminary Results

ANNUAL REPORT AND ACCOUNTS

Alliance Pharma plc (AIM: APH) announces that the Annual Report and Accounts for the year ended 31 December 2020 are now available on the Group's website, www.alliancepharmaceuticals.com

Printed copies will be mailed on or before 9 April 2021 to those shareholders who have opted out of receiving electronic communications.

Printed copies will also be available from Buchanan and may be requested by e-mailing [e-mail] or by telephoning 020 7466 5000.

CORRECTION TO FY2020 PRELIMINARY RESULTS

Following release of the Group's preliminary results for the year ended 31 December 2020 on 23 March 2021, an error in the mathematical calculation of the weighted average number of Ordinary shares was identified.

The correct weighted average number of Ordinary shares for the 12 months ended 31 December 2020 for the Basic EPS calculation is 531,062,798, and not 521,686,254 as originally stated in the preliminary results on 23 March 2021. The correct weighted average number of Ordinary shares for the Diluted EPS calculation is 537,318,838 and not 527,924,294 as originally stated in the preliminary results announcement on 23 March 2021.

This increase in the number of shares results in a small reduction to EPS measures which are correctly stated as follows:

 
 Year ended 31 December 2020                  As stated 
                                  Correctly       on 23 
                                     stated       March 
                                        (p)    2021 (p) 
 Reported basic earnings per 
  share                                1.51        1.54 
-----------------------------  ------------  ---------- 
 Reported diluted earnings 
  per share                            1.49        1.52 
-----------------------------  ------------  ---------- 
 Underlying basic earnings 
  per share                            5.11        5.21 
-----------------------------  ------------  ---------- 
 Underlying diluted earnings 
  per share                            5.05        5.14 
-----------------------------  ------------  ---------- 
 

The corrected numbers have been reflected in the Group's 2020 Annual Report and Accounts and in the version of the FY2020 preliminary results statement available on Alliance's website.

The detail of the EPS calculation is set out in note 10 of the Annual Report and Accounts.

For further information:

 
 Alliance Pharma plc                          + 44 (0)1249 466966 
 Peter Butterfield, Chief Executive 
  Officer 
 Andrew Franklin, Chief Financial Officer 
 www.alliancepharma.co.uk 
 Buchanan                                    + 44 (0)20 7466 5000 
 Mark Court / Sophie Wills / Hannah 
  Ratcliff 
 
 Numis Securities Limited                    + 44 (0)20 7260 1000 
 Nominated Adviser: Freddie Barnfield 
  / Oliver Steele 
 Corporate Broking: James Black 
 
 
 Investec Bank plc                  + 44 (0) 20 7597 5970 
 Corporate Finance: Daniel Adams 
 Corporate Broking: Patrick Robb 
 

About Alliance

Alliance Pharma plc (AIM: APH) is an international healthcare group, headquartered in the UK with subsidiaries in Europe, the Far East and the US and wide international reach through an extensive network of distributors, generating sales in more than 100 countries.

We hold the marketing rights to around 80 Consumer Healthcare brands and Prescription Medicines, which are managed on a portfolio basis according to their growth potential. Promotional investment is focused primarily on our Consumer healthcare brands, many of which have significant international or multi-territory reach. Our Prescription Medicines are generally sold in a more limited number of local markets, and most require little or no promotional investment.

Our strategy allows us to deliver good organic growth and to enhance our growth rate through carefully selected acquisitions.

For more information on Alliance, please visit our website: www.alliancepharmaceuticals.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ACSPPUUGWUPGUMB

(END) Dow Jones Newswires

March 29, 2021 03:13 ET (07:13 GMT)